With FDA approval of self-administered starting and maintenance doses of subcutaneous lecanemab (Leqembi Iqlik) in patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (AD), antiamyloid therapy has moved beyond the infusion chair and into the home.

While the change could eliminate dozens of infusion-center visits over the course of treatment, experts note that it does not turn lecanemab into a simple “take-at-home” drug. MRI monitoring for amyloid-related imaging abnormalities (ARIA), patient and caregiver training, and clinician oversight remain central to treatment, regardless of route of administration.

In the wake of the FDA approval, what should clinicians, patients, and caregivers know about at-home lecanemab dosing?

How Did We Get Here?

In the US, intravenous (IV) lecanemab received accelerated approval in January 2023 and traditional approval that July for patients with MCI or mild AD-related dementia and confirmed amyloid pathology. The regimen is 10 mg/kg every 2 weeks, infused over about an hour.

Then, in August 2025, the agency approved lecanemab as a subcutaneous autoinjector for maintenance treatment after 18 months of initial IV therapy, allowing patients to switch to 360 mg once-weekly injections instead of continuing IV infusions.

A year later, in July 2026, the FDA approved an at-home subcutaneous starting dose that removes the infusion-center requirement altogether. The subcutaneous starting dose is 500 mg (two 250 mg injections) once every week. The maintenance dose is 360 mg once weekly.

What Evidence Supports Home Dosing?

Subcutaneous lecanemab was approved based on data demonstrating that weekly injections provide drug exposure and amyloid reduction comparable to IV administration.

For example, a modeling study reported at the 2025 Clinical Trials on Alzheimer’s Disease Conference indicated that amyloid removal was driven by lecanemab exposure rather than the route of administration, supporting similar amyloid-lowering efficacy with the subcutaneous and IV regimens.

Additional data reported in July at the Alzheimer’s Association International Conference (AAIC) showed that the 500 mg once-weekly subcutaneous dose achieved bioequivalent drug exposure to the 10 mg/kg IV regimen given every 2 weeks, with an exposure ratio of 104% (90% CI, 99.1%-109%). Exposure remained consistent across body weight quartiles, demonstrating a stable pharmacokinetic profile in a broad patient population.

Another AAIC study this year offered the first real-world findings showing that weekly at-home administration of subcutaneous lecanemab was feasible and acceptable. 

Open-label studies involving more than 400 patients showed overall safety on par with IV administration, although injection-site reactions emerged as a route-specific issue.

However, results of a human factor study suggest that training matters. The study showed high injection-success rates among patients and caregivers, although those rates dropped for patients with greater cognitive impairment giving themselves injections without training. 

That finding reinforces the FDA’s decision to make clinician-supervised training and patient selection part of home treatment rather than assuming every patient can self-inject.

How Does It Work?

“Self-administered” does not mean unsupervised from day 1. The FDA requires patients or caregivers to receive direct guidance from a healthcare provider for at least two consecutive subcutaneous doses before home administration. Providers are also advised to reassess that decision periodically. That gives clinicians discretion in deciding whether a patient or caregiver can reliably use the device and follow the dosing schedule.

Gregory Cooper, MD, PhD, chief of adult neurology and director of the Memory Center at Norton Neuroscience Institute in Louisville, Kentucky, generally leaves the choice between IV and subcutaneous treatment to patients and families.

“I have not advised anyone to remain on IV therapy. I don’t feel that one treatment is better than the other, and so allow the patient and their family to decide,” Cooper told Medscape Medical News.

In his experience, a small number of patients or families are uncomfortable giving injections at home or simply prefer coming to an infusion center.

Not all centers are offering home injections from the outset, however.

“We have been offering subcutaneous lecanemab for maintenance therapy but have decided not to offer it as initial therapy,” said Charles Bernick, MD, MPH, senior director of Cognitive Disorders at Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. 

“For those starting therapy, we require using the IV therapy protocol for the first 6 months when the risk of side effects is the highest and four surveillance MRIs need to be done. Once the patient completes 6 months of treatment, they do have the option to switch to subq [subcutaneous],” Bernick told Medscape Medical News.

The autoinjector is used in the abdomen or upper thigh; the back of the upper arm can be used when someone else gives the injection. Sites should be rotated and separated from the previous injection by at least an inch. Patients should avoid irritated, bruised, or injured skin and the area immediately around the navel.

If a weekly dose is missed, the label permits administration up to 6 days late, followed by the next dose on the usual scheduled day.

Although home dosing does not substantially alter his clinic’s workflow during the first 6 months because patients remain on IV therapy, Bernick cautioned that “adherence can definitely be an issue” once dosing moves into the home.

What About ARIA Monitoring?

For patients beginning treatment with subcutaneous lecanemab, the safety-monitoring requirements remain essentially unchanged. The current FDA label requires a baseline MRI and additional MRIs after 1, 2, 3, and 6 months of treatment, regardless of whether lecanemab is given by IV infusion or subcutaneous injection.

Cooper said moving treatment into the home has not changed his approach to monitoring for adverse effects.

“If we are talking about subcutaneous therapy for initiation of treatment, then we will still have the same requirements of frequent MRIs in the first 6 months,” he said, adding that his practice continues to see patients approximately every 6 months, and staff remain available if patients or families have concerns.

The monitoring burden may be lower for patients transitioning to subcutaneous maintenance therapy after prolonged IV treatment. By that point, Cooper said, the risk for serious side effects and ARIA is “very low, and additional testing is only required if unexpected symptoms arise.”

However, home treatment removes the regular infusion-center contact that accompanied IV therapy, making patient and caregiver education important. ARIA can present with headache, confusion, visual changes, dizziness, nausea, gait difficulty, or focal neurologic deficits, although many cases are asymptomatic. Clinicians need to make sure patients and caregivers know which symptoms should prompt an urgent call and when additional MRI evaluation is warranted.

What Should Clinicians Tell Patients?

The key message, Cooper said, is that the route of administration is changing, not the treatment itself.

“They are receiving the same medication, and we expect it to work just as well if received as a subcutaneous injection or an IV infusion,” he said. “The main difference is the way they receive the medication.”

Patients starting lecanemab at home should also understand that subcutaneous administration does not lessen the early safety-monitoring requirements. “We will still have the same safety monitoring requirement if this is being used for initiation of treatment,” Cooper said.

Clinicians should also make sure patients and caregivers understand who will administer the injections, how doses will be tracked, how injection sites should be rotated, what to do after a missed dose, and which symptoms warrant contacting the treatment team.

For some families, the convenience of avoiding regular infusion visits will be a clear advantage. Others may prefer the structure and reassurance of treatment at an infusion center. Cooper said the choice often comes down to patient and family preference, comfort with home injections, and cost.

Will Home Dosing Improve Access?

Data suggest early lecanemab uptake has been sharply skewed toward White, urban, higher-income Medicare patients.

Removing infusion visits could particularly benefit patients who live far from infusion facilities or depend on caregivers for transportation. But the rest of the lecanemab infrastructure remains. Patients still need a diagnosis at the appropriate disease stage, confirmation of amyloid pathology, MRI access, ongoing specialist oversight, and the ability to recognize and report potentially serious adverse events.

Home dosing may therefore reduce one component of the access gap without eliminating the diagnostic and monitoring bottlenecks that precede and accompany treatment.

Bernick was skeptical that home administration alone will substantially improve access. “Home dosing will not likely help access, and in our experience with maintenance dosing, it can be a hassle to get insurance approval. Only when the subcutaneous dosing is shown to save costs will coverage be less of an issue,” he said.

Cooper and Bernick reported having no relevant disclosures.